Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy.
Stalman EW, Wieske L, Keijser JBD, van Dam KPJ, Kummer LYL, Wilbrink MF, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink GJ, van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl AE, Broens B, Parra Sanchez A, van Els CACM, de Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart RCF, Onno Teng YK, van Paassen P, Busch MH, Brusse E, van Doorn PA, Baars AE, Hijnen D, Schreurs CRG, van der Pol WL, Goedee HS, Steenhuis M, Keijzer S, Cristianawati O, Brinke AT, Verstegen NJM, Zwinderman KAH, van Ham SM, Rispens T, Welkers MR, Jonges M, Eftimov F, Kuijpers TW; T2B! immunity against SARS-CoV-2 study group. Stalman EW, et al. Among authors: de leeuw k. J Allergy Clin Immunol. 2024 Sep;154(3):754-766.e7. doi: 10.1016/j.jaci.2024.04.031. Epub 2024 May 17. J Allergy Clin Immunol. 2024. PMID: 38763170 Free article.
Impact of serum high mobility group box 1 and soluble receptor for advanced glycation end-products on subclinical atherosclerosis in patients with granulomatosis with polyangiitis.
Souza AW, de Leeuw K, van Timmeren MM, Limburg PC, Stegeman CA, Bijl M, Westra J, Kallenberg CG. Souza AW, et al. Among authors: de leeuw k. PLoS One. 2014 Apr 28;9(4):e96067. doi: 10.1371/journal.pone.0096067. eCollection 2014. PLoS One. 2014. PMID: 24776932 Free PMC article.
A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
Planting AS, Sonneveld P, van der Gaast A, Sparreboom A, van der Burg ME, Luyten GP, de Leeuw K, de Boer-Dennert M, Wissel PS, Jewell RC, Paul EM, Purvis NB Jr, Verweij J. Planting AS, et al. Among authors: de leeuw k, de boer dennert m. Cancer Chemother Pharmacol. 2005 Jan;55(1):91-9. doi: 10.1007/s00280-004-0854-6. Epub 2004 Jul 28. Cancer Chemother Pharmacol. 2005. PMID: 15565444 Clinical Trial.
Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis.
Tsang-A-Sjoe MW, Nagelkerke SQ, Bultink IE, Geissler J, Tanck MW, Tacke CE, Ellis JA, Zenz W, Bijl M, Berden JH, de Leeuw K, Derksen RH, Kuijpers TW, Voskuyl AE. Tsang-A-Sjoe MW, et al. Among authors: de leeuw k. Rheumatology (Oxford). 2016 May;55(5):939-48. doi: 10.1093/rheumatology/kev433. Epub 2016 Jan 8. Rheumatology (Oxford). 2016. PMID: 26748351
108 results